Evommune, Inc. · NYSE:EVMN
Nan Fung Group Holdings Limited reported a 10.90% stake in Evommune, Inc. (Schedule 13G)
Event Dec 31, 2025 · Filed Feb 13, 2026
Nan Fung Group Holdings Limited reported a 10.90% stake in Evommune, Inc., 3,435,599 shares, as a passive investor on Dec 31, 2025. Filed Feb 13, 2026 (Schedule 13G).
- Stake
- 10.90%
- Shares
- 3,435,599
- Intent
- Passive
- What changed
- Crossed above 5%
- Filed together
- 13 holders
The filing in full
| Holder | Stake | Shares |
|---|---|---|
| Nan Fung Group Holdings Limited | 10.90% | 3,435,599 |
| NF Investment Holdings Limited | 10.70% | 3,367,975 |
| Nan Fung Life Sciences Holdings Limited | 10.70% | 3,367,975 |
| NFLS Platform Holdings Limited | 4.60% | 1,441,032 |
| NFLS Delta III Limited | 4.60% | 1,441,032 |
| Pivotal Life Sciences Holdings Limited | 6.10% | 1,926,943 |
| Pivotal Partners Ltd | 6.10% | 1,926,943 |
| Pivotal bioVenture Partners Fund I U.G.P. Ltd. | 5.20% | 1,632,441 |
| Pivotal bioVenture Partners Fund I G.P., L.P. | 5.20% | 1,632,441 |
| Pivotal bioVenture Partners Fund I, L.P. | 5.20% | 1,632,441 |
| Pivotal bioVenture Partners Fund II G.P. Ltd | 0.90% | 294,502 |
| Pivotal bioVenture Partners Fund II, L.P. | 0.90% | 294,502 |
| NFLS Delta Limited | 4.60% | 1,441,032 |
Source
Related
- Evommune, Inc.
- Pivotal bioVenture Partners Fund I, L.P.
- Evommune, Inc. shareholders
- Form 4 · Pena Luis C. · Oct 15, 2026
- Schedule 13G · T. Rowe Price Associates Inc · Aug 14, 2026
- Schedule 13G/A · Andera Partners · Aug 14, 2026
- Schedule 13G · Point72 Asset Management, L.P. · Jul 16, 2026
- Form 4 · Carver Kyle · Jul 10, 2026